TORONTO, Nov. 26 /PRNewswire-FirstCall/ - GeneNews Limited , a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it will be exhibiting at the Family Medicine Forum 2008 being held at the Sheraton Centre in Toronto from November 27th to November 29th, 2008. GeneNews' exhibit, at booth # 400, will feature the Company's lead product, ColonSentry(TM), the world's first blood-based test to determine a person's current risk for colorectal cancer.
"This event, which attracts more than 1500 family physicians and healthcare professionals, is the premier family medicine conference in Canada and the ideal audience to increase the awareness of ColonSentry(TM) in Canada," said Gailina Liew, Chief Operating Officer of GeneNews. "Building on the expanded roll out of ColonSentry(TM) at additional locations in the Greater Toronto Area last week, our exhibition at the Family Medicine Forum will further support our Canadian commercialization strategy as we plan to offer ColonSentry(TM) in other regions of Canada throughout 2009."
The Family Medicine Forum combines the Annual Scientific Assemblies of the College of Family Physicians of Canada (CFPC), the Ontario College of Family Physicians (OCFP), and the Annual Workshops of the CFPC's Sections of Teachers and Researchers. For additional information please visit ww.fmf.cfpc.ca.
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.
CONTACT: James Smith, (416) 815-0070 x 229, jsmith@equicomgroup.com
